These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1375 related articles for article (PubMed ID: 32959897)

  • 21. CRISPR/Cas system: A game changing genome editing technology, to treat human genetic diseases.
    Hussain W; Mahmood T; Hussain J; Ali N; Shah T; Qayyum S; Khan I
    Gene; 2019 Feb; 685():70-75. PubMed ID: 30393194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review.
    Khatibi S; Sahebkar A; Aghaee-Bakhtiari SH
    Curr Pharm Biotechnol; 2021; 22(4):468-479. PubMed ID: 32564746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
    Ebrahimi V; Hashemi A
    Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly Multiplexed Analysis of CRISPR Genome Editing Outcomes in Mammalian Cells.
    Ishiguro S; Yachie N
    Methods Mol Biol; 2021; 2312():193-223. PubMed ID: 34228292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.
    de Morais CCPL; Correia EM; Bonamino MH; Vasconcelos ZFM
    Hum Gene Ther; 2024 Oct; 35(19-20):781-797. PubMed ID: 39276086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas Advancement in Molecular Diagnostics and Signal Readout Approaches.
    Ahmed MZ; Badani P; Reddy R; Mishra G
    J Mol Diagn; 2021 Nov; 23(11):1433-1442. PubMed ID: 34454111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The landscape of CRISPR/Cas9 for inborn errors of metabolism.
    Leal AF; Fnu N; Benincore-Flórez E; Herreño-Pachón AM; Echeverri-Peña OY; Alméciga-Díaz CJ; Tomatsu S
    Mol Genet Metab; 2023 Jan; 138(1):106968. PubMed ID: 36525790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR: development of a technology and its applications.
    Derry WB
    FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR-Cas9-Mediated Gene Silencing in Cultured Human Epithelia.
    Gago S; Overton NLD; Bowyer P
    Methods Mol Biol; 2021; 2260():37-47. PubMed ID: 33405030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in therapeutic application of CRISPR-Cas9.
    Sun J; Wang J; Zheng D; Hu X
    Brief Funct Genomics; 2020 May; 19(3):164-174. PubMed ID: 31769791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9: at the cutting edge of hepatology.
    Pankowicz FP; Jarrett KE; Lagor WR; Bissig KD
    Gut; 2017 Jul; 66(7):1329-1340. PubMed ID: 28487442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9 for cancer treatment: technology, clinical applications and challenges.
    Cheng X; Fan S; Wen C; Du X
    Brief Funct Genomics; 2020 May; 19(3):209-214. PubMed ID: 32052006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Robust genome editing in adult vascular endothelium by nanoparticle delivery of CRISPR-Cas9 plasmid DNA.
    Zhang X; Jin H; Huang X; Chaurasiya B; Dong D; Shanley TP; Zhao YY
    Cell Rep; 2022 Jan; 38(1):110196. PubMed ID: 34986352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CRISPR/Cas9 for Human Genome Engineering and Disease Research.
    Xiong X; Chen M; Lim WA; Zhao D; Qi LS
    Annu Rev Genomics Hum Genet; 2016 Aug; 17():131-54. PubMed ID: 27216776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.